An observational study in RA - Rheumatoid Arthritis, sponsored by Sohag University. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Sohag University · Observational
This study aims to investigate the expression of Growth Arrest-Specific 5 (GAS5) , a long non-coding RNA , in patients with Rheumatoid Arthritis compared with healthy individuals. The study will also assess the level of Interlukin-6 (IL-6) in the blood and explore the relationship between GAS5 expression and IL-6 levels in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by persistent inflammation of the joints and may result in progressive joint damage and functional impairment. The mechanisms underlying the development and progression of RA involve complex interactions between immune, inflammatory, and molecular pathways.
Long non-coding RNAs (lncRNAs) are regulatory RNA molecules that can influence gene expression and participate in various biological processes, including immune regulation and inflammation. Growth Arrest-Specific 5 (GAS5) is a long non-coding RNA that has been implicated in the regulation of inflammatory and immune-related processes and may have a role in autoimmune diseases.
Interleukin-6 (IL-6) is an important pro-inflammatory cytokine involved in the inflammatory response and pathogenesis of rheumatoid arthritis. Assessment of IL-6 levels may provide information regarding the inflammatory status of patients with RA.
This observational study will compare GAS5 expression and blood IL-6 levels between patients with rheumatoid arthritis and healthy controls. Blood samples will be collected from eligible participants. GAS5 expression will be assessed using quantitative real-time polymerase chain reaction (qRT-PCR), while IL-6 levels will be measured using an enzyme-linked immunosorbent assay (ELISA).
The study will also examine the relationship between these molecular and inflammatory markers and selected clinical and laboratory characteristics of rheumatoid arthritis. The findings may contribute to a better understanding of the molecular mechanisms involved in RA and the potential role of GAS5 and IL-6 in the disease.
Adult patients diagnosed with Rheumatoid Arthritis according to 2010 ACR/EULAR classification criteria and healthy controls participants who meet the predefined eligibility criteria
Exclusion Criteria:
Participants diagnosed with Rhemutoid Arthritis who meet the predefined eligibility criteria and will undergo assessment of GAS5 gene expression and serum interlukin-6 (IL-6) levels
Healthy participants without Rheumatoid Arthritis who meet the predefined eligibilty criteria and will undergo assessment of GAS5 gene expression and serum interlukin-6 (IL-6)
GAS5 gene expression level
GAS5 long non-coding RNA expression level in preipheral blood samples , assessed by quantitative real-time polymerase chain reaction (qRT-PCR) and compared between patients with rheumatoid arthritis and healthy controls
Time frame: at enrollment
No study locations are listed for this record.
Plan to share: Undecided
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sohag University